Truvestments Capital LLC Increases Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Truvestments Capital LLC raised its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 6.4% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 2,562 shares of the medical research company’s stock after buying an additional 155 shares during the quarter. Truvestments Capital LLC’s holdings in Charles River Laboratories International were worth $473,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in the stock. EverSource Wealth Advisors LLC raised its stake in Charles River Laboratories International by 10.2% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,673 shares of the medical research company’s stock valued at $309,000 after buying an additional 155 shares during the last quarter. Cooke & Bieler LP grew its position in shares of Charles River Laboratories International by 42.1% during the 4th quarter. Cooke & Bieler LP now owns 426,767 shares of the medical research company’s stock valued at $78,781,000 after acquiring an additional 126,372 shares during the period. Tortoise Investment Management LLC increased its stake in shares of Charles River Laboratories International by 77.7% in the 4th quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company’s stock worth $49,000 after purchasing an additional 115 shares in the last quarter. Daiwa Securities Group Inc. raised its holdings in Charles River Laboratories International by 7.3% in the 4th quarter. Daiwa Securities Group Inc. now owns 6,820 shares of the medical research company’s stock worth $1,259,000 after purchasing an additional 465 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Charles River Laboratories International by 12.9% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,074 shares of the medical research company’s stock valued at $2,044,000 after purchasing an additional 1,262 shares in the last quarter. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

CRL has been the subject of a number of analyst reports. Robert W. Baird reduced their price target on Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating for the company in a research report on Thursday, February 20th. The Goldman Sachs Group reduced their target price on shares of Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating for the company in a report on Thursday, January 23rd. Bank of America reduced their target price on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a report on Friday, December 13th. Citigroup raised shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and increased their target price for the stock from $155.00 to $175.00 in a report on Tuesday, March 4th. Finally, JPMorgan Chase & Co. reduced their target price on shares of Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating for the company in a report on Thursday, February 20th. One equities research analyst has rated the stock with a sell rating, fifteen have given a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $198.36.

Insider Activity at Charles River Laboratories International

In related news, EVP Joseph W. Laplume sold 4,400 shares of the firm’s stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $162.50, for a total value of $715,000.00. Following the completion of the transaction, the executive vice president now directly owns 20,013 shares of the company’s stock, valued at approximately $3,252,112.50. This trade represents a 18.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO James C. Foster purchased 6,075 shares of the stock in a transaction that occurred on Thursday, February 20th. The stock was bought at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the completion of the transaction, the chief executive officer now owns 183,639 shares of the company’s stock, valued at $30,302,271.39. The trade was a 3.42 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.30% of the stock is currently owned by insiders.

Charles River Laboratories International Trading Up 2.4 %

Shares of CRL opened at $170.70 on Thursday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. Charles River Laboratories International, Inc. has a 1 year low of $150.79 and a 1 year high of $274.77. The company has a 50 day simple moving average of $168.35 and a two-hundred day simple moving average of $185.07. The firm has a market cap of $8.73 billion, a P/E ratio of 1,138.01, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business had revenue of $1 billion during the quarter, compared to analyst estimates of $983.63 million. During the same period last year, the firm posted $2.46 EPS. The company’s revenue was down 1.1% on a year-over-year basis. On average, equities analysts expect that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).